On the risk of delisting of ordinary shares of Annovis Bio, Inc. (ANVS)

The International Trading System Limited (hereinafter – ITS) hereby informs on the delisting risk of ordinary shares of Annovis Bio, Inc. (ISIN US03615A1088, hereinafter – Shares, QI) from New York Stock Exchange LLC (hereinafter - NYSE).  

Information on delisting risk of ordinary shares by NYSE

On March 27, 2025 Annovis Bio, Inc. (hereinafter – the Company) submitted Current report Form 8-K to The United States Securities and Exchange Commission (hereinafter – SEC). According to the report, on March 26, 2025, the Company received a written notice from NYSE notifying the Company that it was not in compliance with the NYSE continued listing standards set forth in Section 802.01B because Company’s average market capitalization over a consecutive 30 trading-day period was less than $50 million and, at the same time, its stockholders’ equity was less than $50 million.

The Notice has no immediate impact on the listing of the Company’s common stock. The Company has 45 days from receipt of the Notice to submit a plan to the NYSE on the definitive action(s) the Company plans to take that would bring it into conformity with the Minimum Market Capitalization Standard within 18 months of receipt of the Notice (hereinafter – Cure Period). If the NYSE accepts the Company’s plan, the NYSE will review the Company on a quarterly basis to confirm compliance with the plan. If the Company’s plan is not accepted, the Company fails to comply with the plan or does not meet the Minimum Market Capitalization Standard at the end of the Cure Period, it will be subject to NYSE’s prompt initiation of suspension and delisting procedures. For more information, please refer to the report available on the SEC website.

Information regarding possible actions to be taken by ITS Ltd.

If NYSE suspends trading in the Company’s ordinary shares, ITS will prohibit submission of orders and will restrict ability to conclude agreements in respect of the Company’s ordinary shares. If the Company’s ordinary shares are delisted from NYSE, ITS will terminate trading in the Company’s ordinary shares. However, in case the Company’s ordinary shares become listed, or admitted to trading on another Recognised Trading Venue, ITS will consider but does not guarantee continuation of trading in the Company’s ordinary shares.